ACSL5 and cutaneous mastocytosis: Our findings suggest that the FAM molecular subtype biomarkers ACSL5, ALOX5AP, CD1D, CD74, IL4I1, and TBXAS1 can be independent predictors of prognosis and immunotherapy response in CM patients.